NASDAQ · Biotechnology · USD
Dogwood Therapeutics, Inc. (DWTX) Stock Analysis
Dogwood Therapeutics, Inc. (DWTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
DWTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.14
- Previous Close
- $1.15
- Day's Range
- 1.13–1.21
- 52-Week Range
- 1.13–7.04
- Volume
- 39.74K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.94
Valuation
- Market Cap
- $39.77M
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$34.26M
- Shares Outstanding
- 33.99M
- 1-Year Return
- −79.22%
Dividend and dates
- Avg Volume
- 69.77K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, DWTX closed at $1.17, −79.22% over 1 year.
Dogwood Therapeutics, Inc. (DWTX) has a market capitalization of $39.77M.
In fiscal 2025, DWTX reported revenue of $0.00.
DWTX Stock Return by Calendar Year
Dogwood Therapeutics, Inc. (DWTX) return since Dec 2020: what $10,000 became
- 1 year
- $10,000 $2,078
- −79.22%
- 5 years
- $10,000 $99
- −99.01%
- Since Dec 2020
- $10,000 $28
- −99.72%
If you had invested $10,000 in Dogwood Therapeutics, Inc. (DWTX) at the close on December 17, 2020, the earliest close on record here, it would have been worth $28 at the close on October 21, 2026: −99.72% in total, −63.43% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −71.88% |
| 2025 | +67.07% |
| 2024 | −82.68% |
| 2023 | +143.64% |
| 2022 | −95.39% |
| 2021 | −31.89% |
| 2020 (partial year) | −55.06% |
As of October 21, 2026.
DWTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$34.26M | — |
| 2024 | $0.00 | −$12.35M | — |
| 2023 | $0.00 | −$5.30M | — |
| 2022 | $0.00 | −$12.25M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$27.97M | −$34.26M | — |
| 2024 | $0.00 | — | −$12.23M | −$12.35M | — |
| 2023 | $0.00 | — | −$5.45M | −$5.30M | — |
| 2022 | $0.00 | — | −$12.32M | −$12.25M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
YahooDogwood Therapeutics Enters Into Securities Subscription Agreement For $5 Investment From CK Life Sciences’ Subsidiary
BenzingaDogwood to Participate in the 2026 Maxim Growth Summit
YahooDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
YahooDogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
SeekingAlphaDogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
MarketBeat
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B